

# CITATION REPORT

List of articles citing

Review article: the global emergence of *Helicobacter pylori* antibiotic resistance

DOI: 10.1111/apt.13497

Alimentary Pharmacology and Therapeutics, 2016, 43, 514-33

**Source:** <https://exaly.com/paper-pdf/64609173/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
464	The role of acid inhibition in eradication. <b>2016</b> , 5,		14
463	A Rapid and Accurate Method to Evaluate Helicobacter pylori Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice. <b>2016</b> , 95, e3458		12
462	A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori. <b>2016</b> , 94, 240-246		30
461	Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: A systematic review and meta-analysis. <i>Journal of Digestive Diseases</i> , <b>2016</b> , 17, 811-819	3.3	21
460	The Toronto Helicobacter pylori Consensus in Context. <b>2016</b> , 151, 9-12		14
459	Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area. <b>2016</b> , 32, 84-90		36
458	Eradication of Helicobacter pylori Infection. <b>2016</b> , 18, 33		18
457	Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen. <b>2016</b> , 51, 66-69		9
456	Arzneimitteltherapie in der Schwangerschaft. <b>2016</b> , 11, 323-333		1
455	Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 1249	6.1	2
454	Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 1249-50	6.1	2
453	Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice. <i>Journal of Digestive Diseases</i> , <b>2016</b> , 17, 670-675	3.3	25
452	High rate of A2142G point mutation associated with clarithromycin resistance among Iranian Helicobacter pylori clinical isolates. <b>2016</b> , 124, 787-93		21
451	Solution NMR studies on Helicobacter pylori proteins for antibiotic target discovery. <b>2016</b> , 11, 681-93		
450	Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. <b>2017</b> , 22, e12374		21
449	ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. <b>2017</b> , 112, 212-239		632
448	Helicobacter pylori treatment: New perspectives using current experience. <b>2017</b> , 8, 123-130		21

447	Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for <i>Helicobacter pylori</i> -related chronic gastritis: a prospective randomized study in China. <b>2017</b> , 23, 391-395	15
446	Phenotypic and Molecular Antimicrobial Susceptibility of <i>Helicobacter pylori</i> . <b>2017</b> , 61,	20
445	[Antimicrobial susceptibility of <i>Helicobacter pylori</i> strains isolated from gastric lesions]. <b>2017</b> , 49, 153-157	1
444	Optimization strategies aimed to increase the efficacy of <i>H. pylori</i> eradication therapies. <b>2017</b> , 22, e12392	40
443	A Novel Stool PCR Test for <i>Helicobacter pylori</i> May Predict Clarithromycin Resistance and Eradication of Infection at a High Rate. <b>2017</b> , 55, 2400-2405	36
442	Practical considerations for managing <i>Helicobacter pylori</i> in college health. <b>2017</b> , 65, 361-362	
441	Probiotics in <i>Helicobacter pylori</i> eradication therapy: Systematic review and network meta-analysis. <b>2017</b> , 41, 466-475	55
440	The Irish <i>Helicobacter pylori</i> Working Group consensus for the diagnosis and treatment of <i>H. pylori</i> infection in adult patients in Ireland. <b>2017</b> , 29, 552-559	23
439	A prospective evaluation of levofloxacin-based triple therapy for refractory <i>Helicobacter pylori</i> infection in Australia. <b>2017</b> , 47, 761-766	8
438	Primary Antibiotic Resistance of <i>Helicobacter pylori</i> in China. <b>2017</b> , 62, 1146-1154	56
437	Population screening and treatment of <i>Helicobacter pylori</i> infection. <b>2017</b> , 14, 230-240	96
436	Management of <i>Helicobacter pylori</i> infection-the Maastricht V/Florence Consensus Report. <b>2017</b> , 66, 6-30	1488
435	In vivo safety evaluation of antibacterial silver chloride nanoparticles from <i>Streptomyces exfoliatus</i> ICN25 in zebrafish embryos. <b>2017</b> , 112, 76-82	16
434	<i>Helicobacter pylori</i> eradication rates of concomitant and sequential therapies in Korea. <b>2017</b> , 22, e12441	13
433	Luminal Clinical. <b>2017</b> , 32, 155-171	1
432	Enrichment of <i>Helicobacter pylori</i> mutant strains after eradication therapy analyzed by gastric wash-based quantitative pyrosequencing. <b>2017</b> , 39, 1010428317734865	4
431	Prevalence, antibiotic resistance, and MLST typing of <i>Helicobacter pylori</i> in Algiers, Algeria. <b>2017</b> , 22, e12446	10
430	Efficacy of three-in-one capsule bismuth quadruple therapy for <i>Helicobacter pylori</i> eradication in clinical practice in a multinational patient population. <b>2017</b> , 22, e12429	10

429	High primary antibiotic resistance of Helicobacter Pylori strains isolated from dyspeptic patients: A prevalence cross-sectional study in Spain. <b>2017</b> , 22, e12440		28
428	Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?. <b>2017</b> , 22, e12438		31
427	Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 773-779	6.1	56
426	Best Practice Recommendations for Diagnosis and Management of Helicobacter pylori-Synthesizing the Guidelines. <b>2017</b> , 15, 648-659		13
425	Characterization of clarithromycin-resistant Helicobacter pylori strains in Iran: A systematic review and meta-analysis. <b>2017</b> , 10, 171-178		14
424	Antibiotic resistance in Helicobacter pylori. <b>2017</b> , 30, 489-497		87
423	Effects of Helicobacter pylori eradication on insulin resistance and metabolic parameters: a systematic review and meta-analysis. <b>2017</b> , 29, 153-159		22
422	Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 550-551	6.1	2
421	Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera ) in third-line rescue treatment for Helicobacter pylori infection. A real-life multicenter study. <b>2017</b> , 22, e12423		9
420	Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. <b>2017</b> , 2, 707-715		124
419	Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. <b>2017</b> , 32, 589-594		22
418	Antibiotic susceptibility, heteroresistance, and updated treatment strategies in infection. <b>2017</b> , 11, 2209-2220		24
417	Novel and Effective Therapeutic Regimens for in an Era of Increasing Antibiotic Resistance. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2017</b> , 7, 168	5.9	66
416	The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication. <b>2017</b> , 56, 1277-1285		27
415	Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of. <b>2017</b> , 2017, 5320180		1
414	Helicobacter pylori ?. <b>2017</b> ,		1
413	Efficacy and safety of sequential versus quadruple therapy as second-line treatment for helicobacter pylori infection-A randomized controlled trial. <b>2017</b> , 12, e0183302		10
412	Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. <b>2017</b> , 12, e0175625		11

411	Update on the first-line treatment for infection - a continuing challenge from an old enemy. <b>2017</b> , 5, 23		15
410	Bacteriocins: antibiotics in the age of the microbiome. <b>2017</b> , 1, 55-63		17
409	First-line therapies for eradication: a critical reappraisal of updated guidelines. <b>2017</b> , 30, 373-379		20
408	Seven-day genotypic resistance-guided triple eradication therapy can be highly effective. <b>2018</b> , 31, 198-204		13
407	Importance of antimicrobial susceptibility testing for the management of eradication in infection. <b>2017</b> , 23, 2854-2869		47
406	Detection of antimicrobial resistance genes of <i>Helicobacter pylori</i> strains to clarithromycin, metronidazole, amoxicillin and tetracycline among Egyptian patients. <b>2018</b> , 19, 417-423		6
405	Repurposing the anthelmintic drug niclosamide to combat <i>Helicobacter pylori</i> . <b>2018</b> , 8, 3701		53
404	Pylera and sequential therapy for first-line <i>Helicobacter pylori</i> eradication: a culture-based study in real clinical practice. <b>2018</b> , 30, 621-625		23
403	Antibiotic resistance pattern of <i>Helicobacter pylori</i> strains isolated in Italy during 2010-2016. <b>2018</b> , 53, 661-664		19
402	A colorimetric broth microdilution method for assessment of <i>Helicobacter pylori</i> sensitivity to antimicrobial agents. <b>2018</b> , 152, 271-278		12
401	<i>Helicobacter pylori</i> purine nucleoside phosphorylase shows new distribution patterns of open and closed active site conformations and unusual biochemical features. <b>2018</b> , 285, 1305-1325		8
400	<i>Helicobacter pylori</i> Infection: An Update for the Internist in the Age of Increasing Global Antibiotic Resistance. <b>2018</b> , 131, 473-479		28
399	Systematic review with meta-analysis: the worldwide prevalence of <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 868-876	6.1	279
398	Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible <i>Helicobacter pylori</i> : A multicenter, prospective, randomized trial. <b>2018</b> , 23, e12456		24
397	Resistance mechanisms of <i>Helicobacter pylori</i> and its dual target precise therapy. <b>2018</b> , 44, 371-392		27
396	Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple <i>Helicobacter pylori</i> therapy despite a high prevalence of antimicrobial resistance. <b>2018</b> , 23, e12485		22
395	Gastric cancer: evidence boosts <i>Helicobacter pylori</i> eradication. <b>2018</b> , 15, 458-460		12
394	Impact of primary antibiotic resistance on the effectiveness of sequential therapy for <i>Helicobacter pylori</i> infection: lessons from a 5-year study on a large number of strains. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1261-1269	6.1	29

393	Helicobacter pylori therapy and clinical perspective. <b>2018</b> , 14, 111-117	13
392	Antimicrobial activity of ellagic acid against Helicobacter pylori isolates from India and during infections in mice. <b>2018</b> , 73, 1595-1603	27
391	Antibiotics resistance of Helicobacter pylori in children with upper gastrointestinal symptoms in Hangzhou, China. <b>2018</b> , 23, e12481	12
390	Antibiotic resistance of Helicobacter pylori to 16 antibiotics in clinical patients. <b>2018</b> , 32, e22339	24
389	In Vitro Antimicrobial Activity and Downregulation of Virulence Gene Expression on Helicobacter pylori by Reuterin. <b>2018</b> , 10, 168-175	27
388	Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens. <b>2018</b> , 23, e12452	12
387	Anti-proliferation effect of blue light-emitting diodes against antibiotic-resistant Helicobacter pylori. <b>2018</b> , 33, 1492-1499	7
386	Propolis: The future therapy against Helicobacter pylori-mediated gastrointestinal diseases. <b>2018</b> , 16, 81-99	12
385	Primary antibiotic resistance of Helicobacter pylori strains among adults and children in a tertiary referral centre in Lithuania. <b>2018</b> , 126, 21-28	10
384	Punctual mutations in gene of clarithromycin-resistant in Colombian populations. <b>2018</b> , 24, 1531-1539	11
383	Efficacy and safety of Sijunzi Decoction for peptic ulcers: A systematic review and meta-analysis. <b>2018</b> , 5, 237-254	1
382	Helicobacter pylori Infection: New Facts in Clinical Management. <b>2018</b> , 16, 605-615	22
381	Outcomes of furazolidone- and amoxicillin-based quadruple therapy for infection and predictors of failed eradication. <b>2018</b> , 24, 4596-4605	11
380	Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review. <b>2018</b> , 41, 654-662	
379	Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review. <b>2018</b> , 41, 654-662	3
378	The efficacy of first-line regimens for Helicobacter pylori eradication in different continents: A systematic review and network meta-analysis protocol. <b>2018</b> , 97, e13682	2
377	Infection and Gastric Dysbiosis: Can Probiotics Administration Be Useful to Treat This Condition?. <b>2018</b> , 2018, 6237239	15
376	Look and Outlook on Enzyme-Mediated Macrolide Resistance. <i>Frontiers in Microbiology</i> , <b>2018</b> , 9, 1942	5.7 33

375	Prevalence of Antibiotic Resistance in <i>Helicobacter pylori</i> : A Systematic Review and Meta-analysis in World Health Organization Regions. <b>2018</b> , 155, 1372-1382.e17	387
374	Fourth-generation quinolones in the treatment of infection: A meta-analysis. <b>2018</b> , 24, 3302-3312	3
373	Current understanding and management of infection: an updated appraisal. <b>2018</b> , 7,	17
372	WITHDRAWN: Efficacy and safety of Sijunzi decoction for peptic ulcers: a systematic review and meta-analysis. <b>2018</b> ,	1
371	Potent Acid Suppression with PPIs and P-CABs: What's New?. <b>2018</b> , 16, 570-590	19
370	Antimicrobial resistance among <i>Helicobacter pylori</i> isolates in Alaska, 2000-2016. <b>2018</b> , 15, 148-153	15
369	Acute upper gastrointestinal bleeding. <b>2018</b> , 363, k4023	6
368	In the quest for new targets for pathogen eradication: the adenylosuccinate synthetase from the bacterium <i>Helicobacter pylori</i> . <b>2018</b> , 33, 1405-1414	3
367	Vitamin C and Infection: Current Knowledge and Future Prospects. <b>2018</b> , 9, 1103	13
366	Acquisition of double mutation in caused high resistance to sitafloxacin in after unsuccessful eradication with sitafloxacin-containing regimens. <b>2018</b> , 6, 391-397	16
365	Future perspective for potential <i>Helicobacter pylori</i> eradication therapies. <b>2018</b> , 13, 671-687	35
364	Hydrotalcite Can Prevent the Damaging Effects of <i>Helicobacter Pylori</i> on Gastric Epithelial Cells. <b>2018</b> , 24, 277-283	1
363	Macrolides, Azalides, and Ketolides. <b>2018</b> , 57-86	
362	<i>Helicobacter pylori</i> drug resistance: therapy changes and challenges. <b>2018</b> , 12, 819-827	37
361	Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for <i>Helicobacter pylori</i> eradication. <b>2018</b> , 17, 29	21
360	Preparation and biological evaluation of metronidazole derivatives with monoterpenes and eugenol. <b>2018</b> , 92, 1954-1962	8
359	Genotyping and antimicrobial resistance patterns of <i>Helicobacter pylori</i> in human and dogs associated with A2142G and A2143G point mutations in clarithromycin resistance. <b>2018</b> , 123, 330-338	4
358	IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. <b>2018</b> , 55, 97-121	22

357	Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. <b>2018</b> , 16, 679-687		41
356	Current eradication rate of with clarithromycin-based triple therapy in a gastroenterology practice in the New York metropolitan area. <b>2018</b> , 11, 205-211		7
355	Helicobacter pylori antimicrobial resistance in a pediatric population. <b>2018</b> , 23, e12528		16
354	Temporal Trends in Helicobacter pylori Eradication Success in a Test-and-Treat Population. <b>2018</b> , 98, 169-174		3
353	Editorial: Helicobacter pylori resistance and sequential therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 95-96	6.1	0
352	Editorial: Helicobacter pylori resistance and sequential therapy-authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 96-97	6.1	3
351	Helicobacter pylori antibiotic resistance in Portugal: Systematic review and meta-analysis. <b>2018</b> , 23, e12493		13
350	Natural Products for the Prevention and Management of Helicobacter pylori Infection. <b>2018</b> , 17, 937-952		21
349	Characterization of clarithromycin heteroresistance among Helicobacter pylori strains isolated from the antrum and corpus of the stomach. <b>2019</b> , 64, 143-151		8
348	Treatment of Helicobacter pylori in Special Patient Populations. <b>2019</b> , 39, 1012-1022		12
347	Prevalence of clarithromycin-resistant in children living in South of Sweden: a 12-year follow-up. <b>2019</b> , 54, 838-842		4
346	Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study. <b>2019</b> , 98, e14408		9
345	Mutations Conferring Resistance to Fluoroquinolones and Clarithromycin among Dyspeptic Patients Attending a Tertiary Hospital, Tanzania. <b>2019</b> , 2019, 8481375		5
344	New insights into resistance of Helicobacter pylori against third- and fourth-generation fluoroquinolones: A molecular docking study of prevalent GyrA mutations. <b>2019</b> , 24, e12628		4
343	Concomitant Infection of S. mansoni and H. pylori Promotes Promiscuity of Antigen-Experienced Cells and Primes the Liver for a Lower Fibrotic Response. <b>2019</b> , 28, 231-244.e5		5
342	Association between parental history of Helicobacter pylori treatment failure and treatment failure in the offspring. <b>2019</b> , 34, 2112-2117		4
341	In Silico and In Vitro Anti- Effects of Combinations of Phytochemicals and Antibiotics. <b>2019</b> , 24,		6
340	An overview of nanotechnology-based treatment approaches against Helicobacter Pylori. <b>2019</b> , 17, 829-840		9



339	Molecular characterization and prevalence of antibiotic resistance in isolates in Kuala Lumpur, Malaysia. <b>2019</b> , 12, 3051-3061		16
338	Favorable outcomes of culture-based <i>Helicobacter pylori</i> eradication therapy in a region with high antimicrobial resistance. <b>2019</b> , 24, e12561		32
337	and Its Antibiotic Heteroresistance: A Neglected Issue in Published Guidelines. <i>Frontiers in Microbiology</i> , <b>2019</b> , 10, 1796	5.7	12
336	Evaluation of the Epidemiologic Efficacy of Eradicating <i>Helicobacter pylori</i> on Development of Gastric Cancer. <b>2019</b> , 41, 97-108		7
335	The rise of antibiotic resistance to <i>Helicobacter pylori</i> in Mexico: Is azithromycin plus levofloxacin the answer?. <i>Revista De Gastroenterología De México (English Edition)</i> , <b>2019</b> , 84, 271-273	0.2	
334	Mutations in the <i>Helicobacter pylori</i> 23S rRNA gene associated with clarithromycin resistance in patients at an endoscopy unit in Medellín, Colombia. <b>2019</b> , 39, 117-129		4
333	Study of inhibitory effects of the mixture of cinnamon and ginger extracts on <i>cagA</i> gene expression of <i>Helicobacter pylori</i> by Real-Time RT-PCR technique. <b>2019</b> , 17, 100493		4
332	Effect of patchouli alcohol on macrophage mediated <i>Helicobacter pylori</i> digestion based on intracellular urease inhibition. <b>2019</b> , 65, 153097		11
331	Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Infection: Meta-Analysis of Randomized Controlled Studies. <b>2019</b> , 8,		14
330	Bismuth supplements as the first-line regimen for <i>Helicobacter pylori</i> eradication therapy: Systemic review and meta-analysis. <b>2019</b> , 24, e12565		32
329	Inhibitors of the Bifunctional 2-C-Methyl-d-erythritol 4-Phosphate Cytidylyl Transferase/2-C-Methyl-d-erythritol-2,4-cyclopyrophosphate Synthase (IspDF) of <i>Helicobacter pylori</i> . <b>2019</b> , 102, e1800228		1
328	Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for <i>Helicobacter pylori</i> Eradication. <b>2019</b> , 58, 1549-1555		6
327	Immunoinformatics Approach to Design a Novel Epitope-Based Oral Vaccine Against. <b>2019</b> , 26, 1177-1190		22
326	Inhibition of Pathogen Adhesion by Bacterial Outer Membrane-Coated Nanoparticles. <b>2019</b> , 58, 11404-11408		63
325	Inhibition of Pathogen Adhesion by Bacterial Outer Membrane-Coated Nanoparticles. <b>2019</b> , 131, 11526-11530		4
324	Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Eradication: A Meta-Analysis of Randomized Clinical Trials. <b>2019</b> , 2019, 9781212		23
323	Study of <i>rdxA</i> and <i>frxA</i> genes mutations in metronidazole-resistant and -susceptible <i>Helicobacter pylori</i> clinical isolates from the central region of Portugal. <b>2019</b> , 17, 300-304		10
322	Potential antigen candidates for subunit vaccine development against <i>Helicobacter pylori</i> infection. <b>2019</b> , 234, 21460-21470		25

321	The rise of <i>Helicobacter pylori</i> resistance to antibiotics in Mexico: Is azithromycin plus levofloxacin the answer?. <b>2019</b> , 84, 271-273	
320	Molecular diagnosis of <i>Helicobacter pylori</i> antibiotic resistance in the Taif region, Saudi Arabia. <b>2019</b> , 63, 199-205	7
319	<i>Helicobacter pylori</i> Mutations Detected by Next-Generation Sequencing in Formalin-Fixed, Paraffin-Embedded Gastric Biopsy Specimens Are Associated with Treatment Failure. <b>2019</b> , 57,	22
318	Reconciliation of Recent <i>Helicobacter pylori</i> Treatment Guidelines in a Time of Increasing Resistance to Antibiotics. <b>2019</b> , 157, 44-53	116
317	Current and Future Treatment of <i>Helicobacter pylori</i> Infections. <b>2019</b> , 1149, 211-225	25
316	First nationwide seroepidemiology and risk factors report of <i>Helicobacter pylori</i> in Jordan. <b>2019</b> , 24, e12572	4
315	Medical Management of Peptic Ulcer Disease. <b>2019</b> , 653-659	1
314	Synergistic effects of nanoparticle heating and amoxicillin on <i>H. pylori</i> inhibition. <b>2019</b> , 485, 95-104	7
313	Are probiotics useful for therapy of <i>Helicobacter pylori</i> diseases?. <b>2019</b> , 64, 99-108	35
312	Alternative eradication regimens for infection in Indonesian regions with high metronidazole and levofloxacin resistance. <b>2019</b> , 12, 345-358	16
311	Twice daily short-message-based re-education could improve <i>Helicobacter pylori</i> eradication rate in young population: A prospective randomized controlled study. <b>2019</b> , 24, e12569	14
310	Detection of the clarithromycin resistance of <i>Helicobacter pylori</i> in gastric mucosa by the amplification refractory mutation system combined with quantitative real-time PCR. <b>2019</b> , 8, 1633-1640	14
309	Inhibition of bacterial toxin recognition of membrane components as an anti-virulence strategy. <b>2019</b> , 13, 4	10
308	Design, synthesis and biological evaluation of <i>Helicobacter pylori</i> inosine 5'-monophosphate dehydrogenase (HpIMP2DH) inhibitors. Further optimization of selectivity towards HpIMP2DH over human IMP2DH. <b>2019</b> , 87, 753-764	2
307	High dose dual therapy versus bismuth quadruple therapy for <i>Helicobacter pylori</i> eradication treatment: A systematic review and meta-analysis. <b>2019</b> , 98, e14396	26
306	Dynamics of <i>Helicobacter pylori</i> infection in infants during the first six months of life. <b>2019</b> , 37, 109-111	4
305	Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of <i>Helicobacter pylori</i> . <b>2019</b> , 24, e12570	29
304	Daphnetin: A Novel Anti- Agent. <b>2019</b> , 20,	12

303	Helicobacter pylori Infection. <b>2019,</b>		
302	Antimicrobial and Anti-Biofilm Effect of an Electrolyzed Superoxidized Solution at Neutral-pH against. <b>2019,</b> 2019, 6154867		3
301	Empirical Helicobacter pylori rescue therapy: an 18-year single-centre study of 1200 patients. <b>2019,</b> 1, 311-324		7
300	Prevalence of Infection and Antibiotic Susceptibility of : An Evaluation in Public and Private Health Systems of Southern Chile. <i>Pathogens,</i> <b>2019,</b> 8,	4-5	7
299	Antibiotic-Resistant Enteric Infections. <b>2019,</b> 33, 1105-1123		13
298	Ulcère $\square$ Helicobacter pylori : efficacit�du traitement et facteurs qui influencent la gu�ison. <b>2019,</b> 54, 342-347		1
297	High Prevalence of Antibiotic Resistance in Iranian Isolates: Importance of Functional and Mutational Analysis of Resistance Genes and Virulence Genotyping. <b>2019,</b> 8,		25
296	Clarithromycin-Susceptible But Virulent Strains Infecting Iranian Patients' Stomachs. <b>2019,</b> 12, 3415-3420		2
295	Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes. <b>2019,</b> 114, 900-906		16
294	Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication. <b>2019,</b> 34, 59-67		16
293	In vitro activity of neem (Azadirachta indica) oil extract against Helicobacter pylori. <b>2019,</b> 232, 236-243		16
292	In vitro and in vivo anti-Helicobacter pylori activity of Casearia sylvestris leaf derivatives. <b>2019,</b> 233, 1-12		19
291	Recent developments in polysaccharides: extraction, purification, structural characteristics and biological activities. <b>2019,</b> 59, S96-S115		31
290	Review of antimicrobial peptides with anti-Helicobacter pylori activity. <b>2019,</b> 24, e12555		32
289	Cochlospermum regium (Mart. ex Schrank) Pilg.: Evaluation of chemical profile, gastroprotective activity and mechanism of action of hydroethanolic extract of its xylopodium in acute and chronic experimental models. <b>2019,</b> 233, 101-114		14
288	Vitamin D3 activates the autolysosomal degradation function against Helicobacter pylori through the PDIA3 receptor in gastric epithelial cells. <b>2019,</b> 15, 707-725		54
287	Design, synthesis, and biological evaluation of Helicobacter pylori inosine 5'-monophosphate dehydrogenase (HpIMPDH) inhibitors. <b>2019,</b> 80, 125-132		10
286	Dynamics of Helicobacter pylori infection in infants during the first six months of life. <b>2019,</b> 37, 109-111		

- 285 Use of microalgae based technology for the removal of antibiotics from wastewater: A review. **2020**, 238, 124680 129
- 284 Increasing Testing for Helicobacter pylori Infection to Improve Quality of Patient Care. **2020**, 18, 1028-1029 0
- 283 Tracking the Virulent Helicobacter pylori Strains Instead of Its Pan-Screening to Prevent Gastric Cancer. **2020**, 10, 315-317
- 282 Helicobacter pylori heteroresistance to clarithromycin in adults-New data by in situ detection and improved concept. **2020**, 25, e12670 5
- 281 Molecular detection of H. pylori antibiotic-resistant genes and molecular docking analysis. **2020**, 34, 610-618 5
- 280 Treatment of with nitazoxanide-containing regimens: a systematic review. **2020**, 52, 381-390 4
- 279 Metronidazole-resistant isolates without mutations obtained from Iranian dyspeptic patients. **2020**, 34, 100636 5
- 278 Making plants into cost-effective bioreactors for highly active antimicrobial peptides. **2020**, 56, 63-70 4
- 277 Delafloxacin against Helicobacter pylori, a potential option for improving eradication success?. **2020**, 96, 114980 1
- 276 : getting to grips with the guidance.. **2021**, 12, 650-655 1
- 275 Procyanidin-Rich Extract from Grape Seeds as a Putative Tool against. **2020**, 9, 9
- 274 The Potential Benefits of Vonoprazan as Infection Therapy. **2020**, 13, 3
- 273 Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of : Randomized ERADICATE Hp Trial. **2020**, 9, 6
- 272 Prospective comparative study between two first-line regimens for Helicobacter pylori eradication: Non-bismuth quadruple versus bismuth quadruple therapy. **2020**, 43, 301-309
- 271 Association between Infection and Diabetes: A Cross-Sectional Study in China. **2020**, 2020, 7201379 1
- 270 Time trends and other sources of variation in Helicobacter pylori infection in mainland China: A systematic review and meta-analysis. **2020**, 25, e12729 9
- 269 Evaluation of multiplex ARMS-PCR for detection of mutations conferring resistance to clarithromycin and levofloxacin. **2020**, 12, 35 10
- 268 Analysis of fitness costs associated with metronidazole and amoxicillin resistance in Helicobacter pylori. **2020**, 25, e12724 2

267	Defining the Disease-Specific Antigenic Repertoire. <i>Frontiers in Microbiology</i> , <b>2020</b> , 11, 1551	5-7	3
266	Empirical or susceptibility-guided treatment for infection? A comprehensive review. <b>2020</b> , 13, 1756284820968736		36
265	Efficacy of bismuth-based quadruple therapy for eradication of <i>Helicobacter pylori</i> infection based on previous antibiotic exposure: A large-scale prospective, single-center clinical trial in China. <b>2020</b> , 25, e12755		1
264	Best Eradication Strategy in the Era of Antibiotic Resistance. <b>2020</b> , 9,		9
263	Telephone-Based Reeducation of Drug Administration for Eradication: A Multicenter Randomized Controlled Study. <b>2020</b> , 2020, 8972473		3
262	Primary and Secondary Genotypic Resistance to Clarithromycin and Levofloxacin Detection in Stools: A 4-Year Scenario in Southern Italy. <b>2020</b> , 9,		5
261	Safety of furazolidone-containing regimen in infection: a systematic review and meta-analysis. <b>2020</b> , 10, e037375		3
260	Efficacy of tailored second-line therapy of eradication in patients with clarithromycin-based treatment failure: a multicenter prospective study. <b>2020</b> , 12, 39		2
259	Secondary Antibiotic Resistance, Correlation between Genotypic and Phenotypic Methods and Treatment in Infected Patients: A Retrospective Study. <b>2020</b> , 9,		3
258	Efficacy of second-line regimens for eradication treatment: a systemic review and network meta-analysis. <b>2020</b> , 7,		2
257	Clinical factors associated with initial <i>Helicobacter pylori</i> eradication therapy: a retrospective study in China. <b>2020</b> , 10, 15403		10
256	Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of <i>Helicobacter pylori</i> infection: A randomized controlled trial. <i>Journal of Digestive Diseases</i> , <b>2020</b> , 21, 549-557	3-3	2
255	Vonoprazan-based triple therapy is effective for <i>Helicobacter pylori</i> eradication irrespective of clarithromycin susceptibility. <b>2020</b> , 55, 1054-1061		7
254	Efficacy of Sucralfate-Combined Quadruple Therapy on Gastric Mucosal Injury Induced by and Its Effect on Gastrointestinal Flora. <b>2020</b> , 2020, 4936318		1
253	High dose PPI-amoxicillin dual therapy for the treatment of infection: a systematic review with meta-analysis. <b>2020</b> , 13, 1756284820937115		8
252	Antibiotic Resistance Results of in a University Hospital: Comparison of the Hybridization Test and Real-Time Polymerase Chain Reaction. <b>2020</b> , 2020, 8853298		1
251	Chitosan Inhibits Growth and Urease Production and Prevents Its Infection of Human Gastric Carcinoma Cells. <b>2020</b> , 18,		1
250	An Updated Systematic Review and Meta-Analysis on the Antibiotic Resistance in Iran (2010-2020). <b>2020</b> , 26, 1186-1194		4

249	Susceptibility-guided therapy for <i>Helicobacter pylori</i> -infected penicillin-allergic patients: A prospective clinical trial of first-line and rescue therapies. <b>2020</b> , 25, e12699	7
248	High Primary Antibiotic Resistance of Strains Isolated from Pediatric and Adult Patients in Poland during 2016-2018. <b>2020</b> , 9,	6
247	Transporters HP0939, HP0497, and HP0471 participate in intrinsic multidrug resistance and biofilm formation in <i>Helicobacter pylori</i> by enhancing drug efflux. <b>2020</b> , 25, e12715	10
246	Discovery of a Novel Mutation in DNA Gyrase and Changes in the Fluoroquinolone Resistance of over a 14-Year Period: A Single Center Study in Korea. <b>2020</b> , 9,	2
245	Next-Generation Sequencing of the Whole Bacterial Genome for Tracking Molecular Insight into the Broad-Spectrum Antimicrobial Resistance of Clinical Isolates from the Democratic Republic of Congo. <b>2020</b> , 8,	10
244	A comparative proteomic approach using metabolic pathways for the identification of potential drug targets against <i>Helicobacter pylori</i> . <b>2020</b> , 42, 519-541	1
243	Optimizing the MIC breakpoints of amoxicillin and tetracycline for antibiotic selection in the rescue therapy of <i>H. pylori</i> with bismuth quadruple regimen. <b>2020</b> , 76, 1581-1589	3
242	Sugar Codes Conjugated Alginate: An Innovative Platform to Make a Strategic Breakthrough in Simultaneous Prophylaxis of GERD and Infection. <b>2020</b> , 14, 2405-2412	
241	Genotypic and Phenotypic Resistance to Clarithromycin in Strains. <b>2020</b> , 9,	6
240	Preventing the Spread of Antibiotic Resistance. <b>2020</b> , 110, 255-259	2
239	Eradication of : the power of nanosized formulations. <b>2020</b> , 15, 527-542	4
238	Clarithromycin Versus Metronidazole in First-Line Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis. <b>2020</b> , 9,	11
237	Evaluation of Antibiotic Resistance of Strains Isolated in Bari, Southern Italy, in 2017-2018 by Phenotypic and Genotyping Methods. <b>2020</b> , 26, 909-917	8
236	Resistance patterns of refractory infection in a referral center in the Delaware Valley. <b>2020</b> , 2, 6-12	5
235	Trends in Primary Antibiotic Resistance in Strains Isolated in Italy between 2009 and 2019. <b>2020</b> , 9,	11
234	Burden of Gastrointestinal Diseases from the Global Perspective. <b>2020</b> , 18, 148	8
233	antibiotic eradication coupled with a chemically defined diet in INS-GAS mice triggers dysbiosis and vitamin K deficiency resulting in gastric hemorrhage. <b>2020</b> , 11, 820-841	11
232	Mutations in the Antibiotic Target Genes Related to Clarithromycin, Metronidazole and Levofloxacin Resistance in Strains from Children in China. <b>2020</b> , 13, 311-322	9

231	A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for <i>Helicobacter pylori</i> rescue treatment. <i>Journal of Digestive Diseases</i> , <b>2020</b> , 21, 256-263	3-3	4
230	Galectin-2 Has Bactericidal Effects against in a B-galactoside-Dependent Manner. <b>2020</b> , 21,		2
229	Ethyl acetate extract of <i>Kaempferia parviflora</i> inhibits <i>Helicobacter pylori</i> -associated mammalian cell inflammation by regulating proinflammatory cytokine expression and leukocyte chemotaxis. <b>2020</b> , 20, 124		2
228	Evaluation of Mutations in 23S rRNA, rdxA and frxA Genes of <i>Helicobacter pylori</i> in Paraffin-Embedded Gastric Biopsy Specimens from Iranian Gastric Cancer and Gastritis Patients. <b>2021</b> , 52, 207-211		1
227	Confirmatory Testing for Eradication of <i>Helicobacter pylori</i> : Challenges and Opportunities. <b>2021</b> , 19, 232-234		1
226	Low Rates of Retesting for Eradication of <i>Helicobacter pylori</i> Infection After Treatment in the Veterans Health Administration. <b>2021</b> , 19, 305-313.e1		6
225	The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of infection. <b>2021</b> , 15, 149-157		2
224	European Registry on <i>Helicobacter pylori</i> management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. <b>2021</b> , 9, 38-46		2
223	Investigation of Clarithromycin Resistance-Associated Mutations and Virulence Genotypes of <i>Helicobacter pylori</i> Isolated from Iranian Population: A Cross-Sectional Study. <b>2021</b> , 78, 244-254		4
222	Antibiotic resistance of <i>Helicobacter pylori</i> in Australia and New Zealand: A systematic review and meta-analysis. <b>2021</b> , 36, 1450-1456		4
221	Dihydrotanshinone I Is Effective against Drug-Resistant <i>Helicobacter pylori</i> and. <b>2021</b> , 65,		7
220	Molecular detection of and clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA <sup>®</sup> GENE assay. <b>2021</b> , 76, 177-183		9
219	GmhB enzyme involved in ADP-heptose biosynthesis pathway is essential for lipopolysaccharide biosynthesis and bacterial virulence. <b>2021</b> , 12, 1610-1628		1
218	Sewage Wastewater and Sludge as Source of Traditional and Emerging Contaminants in Agroecosystems. <b>2021</b> , 35-59		
217	Unraveling antimicrobial resistance in <i>Helicobacter pylori</i> : Global resistome meets global phylogeny. <b>2021</b> , 26, e12782		4
216	Identification of antibiotic resistance patterns in strains isolated from gastric biopsies using real-time PCR and genotypic analysis. <b>2021</b> , 34, 501-509		
215	Phenotypic and Genotypic Antibiotic Resistance Patterns in Strains From Ethnically Diverse Population in Mexico. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2020</b> , 10, 539115	5-9	5
214	Efficacy of butyric acid inclusion in eradication regimens for <i>Helicobacter pylori</i> infection: a meta-analysis of controlled trials. <b>2021</b> , 93, 158-163		2

213	In Vitro Effects of LN66 and Antibiotics Used Alone or in Combination on Mature Biofilm. <b>2021</b> , 9,	4
212	Development, synthesis, and biological evaluation of sulfonyl-L-amino acids as potential anti-Helicobacter pylori and IMPDH inhibitors. <b>2021</b> , 354, e2000385	1
211	Armeniaspirol A: a novel anti-Helicobacter pylori agent. <b>2021</b> ,	4
210	Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area. <b>2021</b> , 36, 2383-2388	1
209	Cost-effectiveness of prevention and early detection of gastric cancer in Western countries. <b>2021</b> , 50-51, 101735	4
208	Fourteen-day sequential therapy is superior to 7-day triple therapy as first-line regimen for Helicobacter pylori infected children. <b>2021</b> , 121, 202-202	1
207	PROBIOTICS IN GASTROINTESTINAL DISEASES: ALL THAT GLITTERS IS NOT GOLD. <b>2021</b> ,	1
206	Antimicrobial effect of local anesthetics on Helicobacter pylori. <b>2021</b> , 5, 230-233	0
205	Design and Optimization of a Novel Strategy for the Local Treatment of Helicobacter pylori Infections. <b>2021</b> , 110, 1302-1309	
204	Virulence Markers, Genotypic versus Phenotypic Resistance and New Treatment Strategies in Helicobacter pylori Infection.	
203	Helicobacter pylori Antimicrobial Resistance and Gene Variants in High- and Low-Gastric-Cancer-Risk Populations. <b>2021</b> , 59,	10
202	Medical Management of Gastroesophageal Reflux Disease. <b>2021</b> , 428-443	1
201	Treatment of Helicobacter pylori infection: a clinical practice update. <b>2021</b> , 112, 281-287	9
200	Helikobakter Pylori Birinci Basamak Tedavisi Alan Hastalarda İFarklı Tedavi Rejiminin Etkinliğinin Değerlendirilmesi. 100-103	
199	Clinical Evaluation of a Real-Time PCR Assay for Simultaneous Detection of Helicobacter pylori and Genotypic Markers of Clarithromycin Resistance Directly from Stool. <b>2021</b> , 59,	11
198	Outer Membrane Vesicles and Extracellular Vesicles from -Infected Cells in Gastric Disease Development. <b>2021</b> , 22,	4
197	Effect of Temperature on Metronidazole Resistance in. <i>Frontiers in Microbiology</i> , <b>2021</b> , 12, 681911	5.7 2
196	Primary antibiotic resistance of Helicobacter pylori isolates is twofold more frequent in HIV-positive than HIV-negative individuals: A descriptive observational study. <b>2021</b> , 10, e1184	1



195	Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications. <b>2021</b> , 18, 613-629		36
194	Antibiotic resistance pattern and frequency of cagA and vacA genes in Helicobacter pylori strains isolated from patients in Tabriz city, Iran. <b>2021</b> , 14, 216		1
193	Comparing the Effect of Two Low-dose and High-dose Four-drug Regimens of Furazolidone in Eradicating. <b>2021</b> , 13, 131-138		
192	The Role of Nitroreductases in Resistance to Nitroimidazoles. <b>2021</b> , 10,		7
191	Analysis of the Primary and Post-Treatment Antibiotic Resistance of Helicobacter pylori in the Nanjing Area. <b>2021</b> , 22, 682-685		2
190	Unraveling the Novel Effect of Patchouli Alcohol Against the Antibiotic Resistance of. <i>Frontiers in Microbiology</i> , <b>2021</b> , 12, 674560	5-7	0
189	Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis. <b>2021</b> , 38, 3937-3947		0
188	The Prevalence of H. Pylori cagA Gene in Patients with Gastric Ulcer. <b>2021</b> , 15, 345-351		
187	Early genetic diagnosis of clarithromycin resistance in. <b>2021</b> , 27, 3595-3608		1
186	Susceptibility-guided versus empirical treatment for Helicobacter pylori infection: A systematic review and meta-analysis. <b>2021</b> , 36, 2649-2658		5
185	Efficacy of Clarithromycin Depends on the Bacterial Density in Clarithromycin-Heteroresistant Infections: An Detected Susceptibility and Quantitative Morphometry-Based Retrospective Study. <b>2021</b> , 27, 1609863		1
184	Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology. <b>2021</b> , 40, 420-444		1
183	Myths and misconceptions in the management of infection.. <b>2022</b> , 13, 245-253		0
182	Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for. <i>Gut and Liver</i> , <b>2021</b> , 15, 528-536	4.8	3
181	Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. <b>2021</b> , 161, 495-507.e4		14
180	Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection. <b>2021</b> , 26, e12840		2
179	Infection and Extragastric Diseases-A Focus on the Central Nervous System. <b>2021</b> , 10,		4
178	Favorable outcomes of rescue second- or third-line culture-based Helicobacter pylori eradication treatment in areas of high antimicrobial resistance. <b>2021</b> , 26, e12844		1

177	Synthesis and characterization of amoxicillin-loaded polymeric nanocapsules as a drug delivery system targeting <i>Helicobacter pylori</i> . <b>2021</b> ,	1
176	infection: from standard to alternative treatment strategies. <b>2021</b> , 1-21	3
175	Minimum inhibitory concentrations of commonly used antibiotics against <i>Helicobacter Pylori</i> : A multicenter study in South China. <b>2021</b> , 16, e0256225	1
174	<i>H.pylori</i> , part II: management in an era of antibiotic resistance. <b>2021</b> , 12, 18-24	
173	A comprehensive method for determining cellular uptake of purine nucleoside phosphorylase and adenylosuccinate synthetase inhibitors by <i>H. pylori</i> . <b>2021</b> , 105, 7949-7967	0
172	Network topology analysis of essential genes interactome of <i>Helicobacter pylori</i> to explore novel therapeutic targets. <b>2021</b> , 158, 105059	5
171	Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. <b>2021</b> ,	1
170	High prevalence of clarithromycin resistant <i>Helicobacter pylori</i> in Turkish children with gastric disorders. <b>2021</b> , 24, 101275	1
169	Evaluating treatments with rifabutin and amoxicillin for eradication of <i>Helicobacter pylori</i> infection in adults: a systematic review. <b>2021</b> , 1-10	0
168	Challenges and solutions in polymer drug delivery for bacterial biofilm treatment: A tissue-by-tissue account. <b>2021</b> , 178, 113973	5
167	A hybrid flood waste classification model using 3D-wavelet transform and support vector machines techniques. 1	0
166	From Inflammation to Cancer: Role of Genetic Polymorphisms of Inflammatory Pathway Molecules in Gastric Cancer. <b>2021</b> , 79-117	
165	An Overview of <i>Helicobacter pylori</i> Infection. <b>2021</b> , 2283, 1-14	5
164	Prospective comparative study between two first-line regimens for <i>Helicobacter pylori</i> eradication: Non-bismuth quadruple versus bismuth quadruple therapy. <b>2020</b> , 43, 301-309	4
163	Rescue Therapies for <i>Helicobacter pylori</i> Infection in Foreign Patients Treated in Italy. <b>2021</b> , 55, 865-868	0
162	Comparison of new and classical point mutations associated with clarithromycin resistance in <i>Helicobacter pylori</i> strains isolated from dyspeptic patients and their effects on phenotypic clarithromycin resistance. <b>2019</b> , 68, 566-573	10
161	Protective effects of membrane vesicles against stress and antimicrobial agents. <b>2020</b> , 166, 751-758	7
160	High prevalence of antibiotic resistance in <i>Helicobacter pylori</i> isolates from Iran: importance of functional and mutational analysis of resistance genes and virulence genotyping.	2

159	Treatment of <i>Helicobacter pylori</i> infection in children: A systematic review. <b>2020</b> , 8, 292-308		1
158	Randomised clinical trial comparing concomitant and hybrid therapy for eradication of <i>Helicobacter pylori</i> infection. <b>2020</b> , 15, e0244500		2
157	Urban-Rural Disparities and Temporal Trends in Peptic Ulcer Disease Epidemiology, Treatment, and Outcomes in the United States. <b>2021</b> , 116, 296-305		1
156	Comparative Evaluation of RUT, PCR and ELISA Tests for Detection of Infection with Cytotoxigenic <i>H. pylori</i> . <b>2016</b> , 6, 261-6		11
155	[Molecular genetic predictors of resistance to anti- <i>Helicobacter pylori</i> therapy]. <b>2017</b> , 89, 5-12		9
154	Efficacy and tolerability of fourteen-day sequential quadruple regimen: pantoprazole, bismuth, amoxicillin, metronidazole and or furazolidone as first-line therapy for eradication of : a randomized, double-blind clinical trial. <b>2019</b> , 18, 644-652		5
153	Tailored <i>Helicobacter pylori</i> eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance. <b>2019</b> , 111, 655-661		6
152	Hellenic consensus on infection. <b>2020</b> , 33, 105-124		9
151	Role of food in environmental transmission of. <b>2017</b> , 8, 146-152		9
150	Antibiotic resistance of <i>Helicobacter pylori</i> infection in a children's hospital in Vietnam: prevalence and associated factors. <b>2020</b> , 111, 498-501		1
149	Comparison of the Diagnostic Performance of qPCR, Sanger Sequencing, and Whole-Genome Sequencing in Determining Clarithromycin and Levofloxacin Resistance in. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2020</b> , 10, 596371	5.9	11
148	Using Probiotics as Supplementation for Antibiotic Therapy. <b>2020</b> , 21,		33
147	Genomic Analysis of Antimicrobial Resistance Genotype-to-Phenotype Agreement in. <b>2020</b> , 9,		5
146	Antimicrobial susceptibility testing before first-line treatment for infection in patients with dual or triple antibiotic resistance. <b>2017</b> , 23, 3367-3373		16
145	Development of treatment: How do we manage antimicrobial resistance?. <b>2019</b> , 25, 1907-1912		30
144	Review of current diagnostic methods and advances in diagnostics in the era of next generation sequencing. <b>2019</b> , 25, 4629-4660		44
143	Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for eradication: A prospective open-label randomized trial. <b>2019</b> , 25, 6790-6798		10
142	Sequential versus concomitant therapy for eradication of <i>Helicobacter Pylori</i> in patients with perforated duodenal ulcer: A randomized trial. <b>2016</b> , 22, 309-15		14

141	Developing New Antimicrobial Therapies: Are Synergistic Combinations of Plant Extracts/Compounds with Conventional Antibiotics the Solution?. <b>2017</b> , 11, 57-72	203
140	Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China. <b>2017</b> , 23, 275-280	18
139	Efficacy and Tolerability of Second-Line Metronidazole Triple Therapy Using Vonoprazan for Helicobacter pylori Eradication in Japan—Comparative Study: Vonoprazan vs. Proton Pump Inhibitors. <b>2018</b> , 08, 27-38	2
138	Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for Infection: A Nationwide Randomized Trial in Korea. <i>Gut and Liver</i> , <b>2019</b> , 13, 531-540	4.8 29
137	Timing of prior exposure to antibiotics and failure of Helicobacter pylori eradication: a population-based study. <b>2021</b> ,	1
136	Therapeutic Potential of Sitafloxacin as a New Drug Candidate for Eradication in Korea: An In Vitro Culture-Based Study. <b>2021</b> , 10,	0
135	Detection of CYP2C19*2_ allele among Helicobacter pylori -infected patients in two tertiary hospitals of Khartoum, Sudan, 2019. 10, 1063	
134	Development and Validation of Multiplex Quantitative PCR Assay for Detection of and Mutations Conferring Resistance to Clarithromycin and Levofloxacin in Gastric Biopsy. <b>2021</b> , 14, 4129-4145	3
133	Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections. <b>2021</b> , 21, 388	4
132	Potential utility of nano-based treatment approaches to address the risk of. <b>2021</b> , 1-18	2
131	Revisiting Therapeutic Strategies for Treatment in the Context of Antibiotic Resistance: Focus on Alternative and Complementary Therapies. <b>2021</b> , 26,	6
130	Antimicrobial resistance and virulence in Helicobacter pylori: Genomic insights. <b>2021</b> , 113, 3951-3966	3
129	Molecular Detection of H.pylori Antibiotic-Resistant Genes and Bioinformatics Predictive Analysis.	
128	A comparison between conventional triple therapy and sequential therapy on tolerance of treatment and eradication of Helicobacter pylori infection in Egyptian patients. <b>2018</b> , 30, 90-95	1
127	Rabeprazole in the treatment of duodenal ulcer disease and functional dyspepsia. <b>2018</b> , 70-76	
126	The use of a virus-derived targeting peptide to selectively kill staphylococcus bacteria with antimicrobial peptides.	
125	Making plants into cost-effective bioreactors for highly active antimicrobial peptides.	
124	[Underwater rocks of anti - helicobacter therapy]. <b>2019</b> , 91, 141-147	3

123	Influence of parental compliance on the effectiveness of treatment of chronic gastroduodenal pathology in children. <b>2019</b> , 5, 69-74	
122	Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection. <b>2020</b> , 26, 78-83	1
121	Antibiotic Resistance of Helicobacter pylori Isolated from Patients after Partial Gastrectomy: A Retrospective Study. <b>2021</b> , 32, 996-1002	1
120	Host genetic and environmental factors shape the human gut resistome.	1
119	Global and Temporal Trends in the Use of Antibiotics and Spread of Antimicrobial Resistance. <b>2020</b> , 81-94	1
118	Cholesterol glucosylation-based survival strategy in Helicobacter pylori. <b>2021</b> , 26, e12777	2
117	Modern aspects of eradication therapy. <b>2020</b> , 36-45	
116	Helicobacter pylori Infection: When Should It Be Treated?. <b>2020</b> , 81-102	0
115	Safety and Efficacy of Nitazoxanide-Based Regimen for the Eradication of Infection: A Systematic Review and Meta-Analysis. <b>2020</b> , 13, 260-268	5
114	PRIMARY GASTRIC LYMPHOMAS. <b>2020</b> , 13, 95-103	1
113	Relationship Between Recreational Cannabis Use and Infection. <b>2021</b> ,	
112	Correlation between clarithromycin resistance, virulence factors and clinical characteristics of the disease in Helicobacter pylori infected patients in Shahrekord, Southwest Iran. <b>2021</b> , 11, 147	1
111	In vitro antibacterial activity of nimbolide against Helicobacter pylori. <b>2021</b> , 285, 114828	3
110	Impact of previous metronidazole exposure on metronidazole-based second-line quadruple therapy for Helicobacter pylori infection. <b>2020</b> , 35, 1094-1103	2
109	Evaluation of antimicrobial susceptibility and integron carriage in isolates from patients. <b>2016</b> , 9, S47-S52	8
108	Helicobacter pylori infection: old and new. <b>2017</b> , 10, 112-117	38
107	Management of multi-drug resistant infection by supplementary, complementary and alternative medicine; a review. <b>2017</b> , 10, S8-S14	3
106	Correlation Analysis of Infection and Digestive Tract Symptoms in Children and Related Factors of Infection. <b>2020</b> , 49, 1912-1920	

105	Socioeconomic and demographic factors associated with failure in eradication using the standard triple therapy. <b>2021</b> , 14, 53-58	
104	Treatment of infection in the presence of penicillin allergy.. <b>2021</b> , 27, 7661-7668	0
103	Tailored susceptibility-guided therapy via gastric juice PCR for the first-line H. pylori eradication, a randomized controlled trial. <b>2021</b> ,	0
102	Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD. <b>2021</b> , e12862	
101	High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection [A review of the strengths, weaknesses, and proposed solutions. <b>2021</b> ,	1
100	A review [plant essential oils active against Helicobacter pylori. 1-13	1
99	Correlation Analysis of Helicobacter pylori Infection and Digestive Tract Symptoms in Children and Related Factors of Infection. <b>2020</b> , 49, 1912-1920	
98	Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms.. <b>2022</b> , 53, 33	6
97	Gallium (III) Complexes in Cancer Chemotherapy.	1
96	Efficacy of Twice a Day Bismuth Quadruple Therapy for Second-Line Treatment of Infection.. <b>2022</b> , 12,	
95	In silico design and in vitro assessment of anti-Helicobacter pylori compounds as potential small-molecule arginase inhibitors.. <b>2022</b> , 1	0
94	Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against : A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles.. <b>2022</b> , 14,	0
93	High level of resistance to metronidazole and clarithromycin among Helicobacter pylori clinical isolates in Qazvin province, Iran. <b>2022</b> , 26, 101494	
92	In vitro anti-Helicobacter pylori activity of Syzygium aromaticum and the preliminary mechanism of action.. <b>2022</b> , 288, 114995	1
91	Effects of enhanced education for patients with the Helicobacter pylori infection: A systematic review and meta-analysis.. <b>2022</b> , e12880	2
90	Factors Affecting the Intraluminal Therapy for Infection.. <b>2022</b> , 10,	1
89	Exploration of the molecular mechanisms underlying the antibiotic resistance of Helicobacter pylori: A whole-genome sequencing-based study in Southern China.. <b>2022</b> , e12879	1
88	Characterization of Metronidazole-Resistant Lines by Comparative Transcriptomics and Proteomics.. <i>Frontiers in Microbiology</i> , <b>2022</b> , 13, 834008	5.7 0

87	Experimental design and optimization of a novel dual-release drug delivery system with therapeutic potential against infection with <i>Helicobacter pylori</i> .. <b>2022</b> , 213, 112403		0
86	Worldwide and Regional Efficacy Estimates of First-line <i>Helicobacter pylori</i> Treatments: A Systematic Review and Network Meta-Analysis. <b>2021</b> , 56,		0
85	IMPROVEMENT OF ERADICATION THERAPY IN CHILDREN WITH DUODENAL ULCER ASSOCIATED WITH <i>HELICOBACTER PYLORI</i> . <b>2022</b> , 75, 215-222		
84	Second line therapy for <i>Helicobacter pylori</i> eradication: state of art.. <b>2022</b> ,		0
83	Nuclease activity: an exploitable biomarker in bacterial infections.. <b>2022</b> ,		0
82	Investigation of Plant Antimicrobial Peptides against Selected Pathogenic Bacterial Species Using a Peptide-Protein Docking Approach.. <b>2022</b> , 2022, 1077814		
81	Correlation Analysis Among Genotype Resistance, Phenotype Resistance, and Eradication Effect After Resistance-Guided Quadruple Therapies in Refractory Infections.. <i>Frontiers in Microbiology</i> , <b>2022</b> , 13, 861626	5.7	
80	Investigating the effect of quadruple therapy with <i>Saccharomyces boulardii</i> or <i>Lactobacillus reuteri</i> strain (DSMZ 17648) supplements on eradication of <i>Helicobacter pylori</i> and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial.. <b>2022</b> , 22, 107		1
79	Interplay between Amoxicillin Resistance and Osmotic Stress in <i>Helicobacter pylori</i> .. <b>2022</b> , e0004522		
78	Delivering macrolide antibiotics to heal a broken heart - And other inflammatory conditions.. <b>2022</b> , 184, 114252		0
77	Ninety-four thousand-case retrospective study on antibacterial drug resistance of .. <i>World Journal of Clinical Cases</i> , <b>2021</b> , 9, 10838-10849	1.6	0
76	Increasing <i>Helicobacter pylori</i> clarithromycin resistance in Australia over 20 years. <b>2021</b> ,		2
75	Identification of B-Cell Epitopes of HspA from and Detection of Epitope Antibody Profiles in Naturally Infected Persons.. <b>2021</b> , 10,		
74	RP-HPLC-DAD Method Development and Validation for Simultaneous Determination of Lansoprazole, Tinidazole, Amoxicillin and Naproxen in Their Raw Materials and Combined Dosage Form: DOE Approach for Optimization of the Proposed Method.. <b>2021</b> ,		2
73	The Efficacy of Probiotics in the Management of <i>Helicobacter Pylori</i> : A Systematic Review.. <b>2021</b> , 13, e20483		0
72	Table_1.XLSX. <b>2020</b> ,		
71	Table_2.XLSX. <b>2020</b> ,		
70	Table_3.XLSX. <b>2020</b> ,		

69	Factors Affect the Eradication Rate of by Modified Quadruple Therapy: A Prospective Cohort Study.. <b>2022</b> , 15, 2339-2345		0
68	Tratamiento empírico vs tratamiento basado en susceptibilidad para erradicar H.pylori: ¿es posible cambiar este paradigma usando métodos moleculares modernos?. <b>2022</b> ,		
67	Eradication Rate Using a First-line Triple Therapy for Helicobacter pylori Infection in Yeongdong, Gangwon Province, Korea.		0
66	A Survey of Helicobacter pylori Antibiotic-Resistant Genotypes and Strain Lineages by Whole-Genome Sequencing in China.		0
65	Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. <i>Alimentary Pharmacology and Therapeutics</i> ,	6.1	3
64	Comparative Effectiveness of Various Eradication Regimens for Helicobacter Pylori Infection in the Northeastern Region of Poland. <i>International Journal of Environmental Research and Public Health</i> , <b>2022</b> , 19, 6921	4.6	0
63	Are pro- and/or synbiotics beneficial in Helicobacter pylori eradication therapy in children? A narrative review. <i>European Journal of Pediatrics</i> ,	4.1	1
62	Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. <i>Frontiers in Microbiology</i> , 13,	5.7	2
61	Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. <i>World Journal of Clinical Cases</i> , <b>2022</b> , 10, 6349-6359	1.6	1
60	Development and Validation of an Analytical Method for &#946;-Agonists in Livestock and Fishery Products Using LC-MS/MS. <i>Korean Journal of Environmental Agriculture</i> , <b>2022</b> , 41, 135-151	0.6	
59	The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications. <i>Frontiers in Pharmacology</i> , 13,	5.6	1
58	Empiric treatment vs susceptibility-guided treatment for eradicating H. pylori: Is it possible to change that paradigm using modern molecular methods?. <i>Revista De Gastroenterología De México (English Edition)</i> , <b>2022</b> ,	0.2	
57	In Vitro Activity of the Arylaminoartemisinin GC012 against Helicobacter pylori and Its Effects on Biofilm. <i>Pathogens</i> , <b>2022</b> , 11, 740	4.5	0
56	Efficacy of Shugan Hewei Therapy for Chronic Atrophic Gastritis: A Systematic Review and Meta-Analysis. <i>Chinese Medicine and Culture</i> , <b>2022</b> , 5, 97-109	0.1	
55	Altered virome structure and function characterization in Helicobacter pylori-driven colorectal carcinogenesis and H. pylori eradication.		
54	Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial. <i>Gut and Liver</i> , <b>2022</b> , 16, 535-546	4.8	2
53	Saccharomyces boulardii Allows Partial Patients to Avoid Reusing Bismuth Quadruple for Helicobacter pylori Rescue Therapy: A Single-Center Randomized Controlled Study. <i>Frontiers in Cellular and Infection Microbiology</i> , 12,	5.9	
52	Clinical practice of Helicobacter pylori infection management by gastroenterologists in secondary and tertiary hospitals: A stratified sampling cross-sectional survey. <i>Journal of Digestive Diseases</i> ,	3.3	



- 51 Changing profile of *Helicobacter pylori* primary antibiotic resistance in Singapore over two decades. **2022**, 23, 295-301
- 50 Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed *Helicobacter pylori* Infection as 14 Days of Bismuth-Based Quadruple Therapy. **2022**, 11, 4440
- 49 Multiple amino acid substitutions in penicillin-binding protein-1A confer amoxicillin resistance in refractory *Helicobacter pylori* infection. **2022**,
- 48 Glycyrrhizin, an inhibitor of HMGB1 induces autolysosomal degradation function and inhibits *H. pylori* infection.
- 47 Optimized dual therapy for treatment-naïve patients of *Helicobacter pylori* infection: A large-scale prospective, multicenter, open-label, randomized controlled study. ○
- 46 Chemical Synthesis of the Highly Sterically Hindered Core Undecasaccharide of *Helicobacter pylori* Lipopolysaccharide for Antigenicity Evaluation with Human Serum. **2022**, 144, 14535-14547 1
- 45 Efficacy and safety of vonoprazan-based quadruple therapy for the eradication of *Helicobacter pylori* in patients with peptic ulcers: a pooled analysis of two randomized, double-blind, double-dummy, phase 3 trials.
- 44 Prevalence of antibiotic heteroresistance associated with *Helicobacter pylori* infection: A systematic review and meta-analysis. **2022**, 170, 105720 ○
- 43 Efficacy and safety of high-dose esomeprazole+amoxicillin dual therapy for *Helicobacter pylori* rescue treatment: a multicenter, prospective, randomized, controlled trial. **2022**, 135, 1707-1715 ○
- 42 Are molecular methods helpful for the diagnosis of *Helicobacter pylori* infection and for the prediction of its antimicrobial resistance?. 13, ○
- 41 Current and Future Perspectives in the Diagnosis and Management of *Helicobacter pylori* Infection. **2022**, 11, 5086 1
- 40 Short-term outcomes and intermediate-term follow-up of *Helicobacter pylori* infection treatment for naïve patients: a retrospective observational study. **2022**, 12, e062096 ○
- 39 Antibiotic resistance patterns of *Helicobacter pylori* in North Israel: A six-year study. ○
- 38 Rates of Antimicrobial Resistance in *Helicobacter pylori* Isolates from Clinical Trial Patients Across the US and Europe. **2022**, Publish Ahead of Print, ○
- 37 Silicon Nanostructures and Nanocomposites for Antibacterial and Theranostic Applications. **2022**, 113912 ○
- 36 Clinical Implications of *Helicobacter pylori* Antibiotic Resistance in Italy: A Review of the Literature. **2022**, 11, 1452 2
- 35 Drug-resistant bacteria from farm to fork: impact of antibiotic use in animal production. **2023**, 871-892 ○
- 34 The impacts of probiotics in eradication therapy of *Helicobacter pylori*. **2022**, 204, ○

- 33 Cohort profile: Nordic Helicobacter Pylori eradication project (NordHePEP). 1-7 0
- 32 Anti-Inflammatory Effect of Korean Propolis on Helicobacter pylori-Infected Gastric Mucosal Injury Mice Model. **2022**, 14, 4644 1
- 31 Preparation, Characterization, and Anti-Adhesive Activity of Sulfate Polysaccharide from Caulerpa lentillifera against Helicobacter pylori. **2022**, 14, 4993 0
- 30 Phototherapy and Mechanism Exploration of Biofilm and Multidrug-Resistant Helicobacter pylori by Bacteria-Targeted NIR Photosensitizer. 2205248 0
- 29 Evaluation of clarithromycin and levofloxacin resistance of Helicobacter pylori strains isolated from patients at the Hospital for Tropical Diseases, Ho Chi Minh City. 33-42 0
- 28 The Quinone-Derived Small Molecule M5N32 Is an Effective AntiHelicobacter pylori Agent Both In Vivo and In Vitro. **2022**, 226, S493-S502 0
- 27 Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg). gutjnl-2022-328232 0
- 26 An eco-friendly multi-analyte high-performance thin layer chromatographic densitometric determination of amoxicillin, metronidazole, and famotidine in their ternary mixtures and simulated gastric juice: A promising protocol for eradicating Helicobacter pylori. 0
- 25 Prevalence and trends of multiple antimicrobial resistance of Helicobacter pylori in one tertiary hospital for 20 years in Korea. 0
- 24 Lactobacillus rhamnosus GG supplementation on eradication rate and dyspepsia in Helicobacter pylori infection treated with three-in-one bismuth quadruple therapy. 13, 0
- 23 Treatment of Acid-related Diseases Using Potassium-competitive Acid Blockers. **2022**, 80, 247-253 0
- 22 Equilibrium, kinetics, and thermodynamics study on the biosorption of reactive levofloxacin antibiotic on Pithophora macroalgae in aqueous solution. **2023**, 195, 0
- 21 A Vonoprazan, Clarithromycin, and Metronidazole Regimen as &lt;i>Helicobacter pylori</i> Eradication Therapy for Patients with Penicillin Allergy in Light of Clarithromycin Resistance. **2023**, 1 1
- 20 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Publish Ahead of Print, 0
- 19 Quantitative Multiplex Real-Time Polymerase Chain Reaction Assay for the Detection of Helicobacter pylori and Clarithromycin Resistance. 0
- 18 IgY antibodies: The promising potential to overcome antibiotic resistance. 14, 1 1
- 17 Multiplex PCR-ASE functionalized microfluidic diagnostic platform for the detection of clarithromycin resistance mutations in Helicobacter pylori. **2023**, 387, 133808 0
- 16 Helicobacter pylori Virulence Factors and Clarithromycin Resistance-Associated Mutations in Mexican Patients. **2023**, 12, 234 0

- 15 Current Worldwide Trends in Pediatric *Helicobacter pylori* Antimicrobial Resistance. **2023**, 10, 403 ○
- 14 Effect of fermentation on antioxidant, antimicrobial, anti-inflammatory, and anti-*Helicobacter pylori* adhesion activity of *Ulmus davidiana* var. *japonica* root bark. ○
- 13 A New Option in *Helicobacter pylori* eradication: High-dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting. ○
- 12 Evaluation of RUT, and ELISA Tests for Detection of *Helicobacter pylori* in Dyspeptic Patients Visiting a Tertiary Care Hospital, South India. **2023**, 17, 543-548 ○
- 11 In Search for Reasons behind *Helicobacter pylori* Eradication Failure: Assessment of the Antibiotics Resistance Rate and Co-Existence of *Helicobacter pylori* with *Candida* Species. **2023**, 9, 328 ○
- 10 Development of apigenin loaded gastroretentive microsphere for the targeting of *Helicobacter pylori*. **2023**, ○
- 9 Drug Resistance Patterns of Commonly Used Antibiotics for the Treatment of *Helicobacter pylori* Infection among South Asian Countries: A Systematic Review and Meta-Analysis. **2023**, 8, 172 ○
- 8 The Anti-*Helicobacter pylori* effects of *Limosilactobacillus reuteri* strain 2892 isolated from Camel milk in C57BL/6 mice. **2023**, 39, ○
- 7 A review on the research progress on non-pharmacological therapy of *Helicobacter pylori*. 14, ○
- 6 RdxA Diversity and Mutations Associated with Metronidazole Resistance of *Helicobacter pylori*. **2023**, 11, ○
- 5 Effectiveness of 7-day triple therapy with half-dose clarithromycin for the eradication of *Helicobacter pylori* without the A2143G and A2142G point mutations of the 23S rRNA gene in a high clarithromycin resistance area. 10, ○
- 4 Effects of prior antibiotic use on clarithromycin resistance in *Helicobacter pylori*. ○
- 3 Effectiveness of empirical <i>Helicobacter pylori</i> eradication therapy with furazolidone in Russia: results from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg). **2023**, 95, 120-129 ○
- 2 Glycyrrhizin, an inhibitor of HMGB1 induces autolysosomal degradation function and inhibits *Helicobacter pylori* infection. **2023**, 29, ○
- 1 Characteristics of phenotypic antibiotic resistance of *Helicobacter pylori* and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia. ○